Core Viewpoint - A class action lawsuit has been initiated against Lantheus Holdings, Inc. due to allegations of misleading statements regarding the competitive position of its product Pylarify, which led to inflated stock prices and subsequent losses for investors [1][3]. Company Performance - Lantheus reported disappointing first quarter results on May 7, 2025, with Pylarify's performance falling short of market expectations [4]. - On August 6, 2025, Lantheus announced further disappointing results, revealing an 8.3% year-over-year decline in Pylarify's performance and significantly reduced growth projections for fiscal year 2025 [4]. Stock Market Reaction - Following the negative announcements, Lantheus' stock price plummeted from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025, marking a decline of approximately 28.8% in just one day [5].

Core Viewpoint - A securities fraud lawsuit has been filed against Lantheus Holdings Inc. and its executives, alleging that they misled investors regarding the performance and pricing of its key product, Pylarify, leading to significant stock price declines [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Lantheus and its executives provided false assurances about Pylarify's market leadership and pricing strength, while concealing competitive pressures and price erosion [2]. - Following the release of disappointing quarterly results in May and August 2025, Lantheus' stock experienced declines of over 23% and 28%, respectively, due to reduced revenue guidance and increased competition [2]. Group 2: Investor Eligibility - Investors who purchased Lantheus Holdings Inc. common stock between February 26, 2025, and August 5, 2025, and have experienced losses may be eligible to participate in the lawsuit, regardless of whether they sold their shares [3]. Group 3: Next Steps for Investors - The deadline for investors to seek appointment as lead plaintiff is November 10, 2025, and a class has not yet been certified [4]. - Investors are encouraged to contact Block & Leviton for more information on how to proceed if they have incurred losses [4]. Group 4: Whistleblower Information - Individuals with non-public information about Lantheus Holdings Inc. are encouraged to assist in the investigation or report to the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [5]. Group 5: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [6].

Question-and-Answer SessionSo for those in the audience who aren't familiar with the Lantheus story, can you mind just giving me a quick background on the company?Brian MarkisonCEO & Director Yes. So a quick background. Also, please note our safe harbor and forward-looking statements, please. Background on the company, founded coming out of the Manhattan project, had a number of different names over time, but always been in the nuclear medicine business, always leadership going back in time with products li ...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Lantheus Holdings, Inc. ("Lantheus†or the "Company†) (NASDAQ:LNTH) investors concerning the Company's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On August 6, 2025, Lantheus announced disappointing second quarter 2025 results, revealing earnings-per-share ("EPS†) and revenue figures that m. ...

Question-and-Answer SessionSo for those in the audience who aren't familiar with the Lantheus story, can you mind just giving me a quick background on the company?Brian MarkisonCEO & Director Yes. So a quick background. Also, please note our safe harbor and forward-looking statements, please. Background on the company, founded coming out of the Manhattan project, had a number of different names over time, but always been in the nuclear medicine business, always leadership going back in time with products li ...

Lantheus (NasdaqGM:LNTH) FY Conference September 09, 2025 07:00 AM ET Company ParticipantsBrian Markison - CEO & DirectorRobert Marshall - Chief Financial OfficerConference Call ParticipantsNone - AnalystNoneThank you all for coming. Welcome to the Morgan Stanley Healthcare Conference. Just a quick note on disclosure. For important disclosures, please see the Morgan Stanley Research Disclosure website or please contact your Morgan Stanley sales representative. Thank you for attending the Lantheus fireside. ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Lantheus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information ...

Core Viewpoint - The Schall Law Firm is investigating Lantheus Holdings, Inc. for potential violations of securities laws following disappointing Q2 2025 earnings results and a significant drop in share price [1][2]. Group 1: Investigation Details - The investigation centers on whether Lantheus made false or misleading statements and failed to disclose important information to investors [2]. - Following the announcement of Q2 2025 earnings on August 6, 2025, Lantheus reported revenue and earnings per share that fell short of expectations, leading to a nearly 28.6% decline in share price on the same day [2]. Group 2: Financial Performance - Lantheus lowered its guidance for full year revenue and diluted earnings per share, indicating a negative outlook for the company's financial performance [2].

Company Overview - Lantheus Holdings, Inc. is a leading radiopharmaceutical-focused company dedicated to enabling clinicians to Find, Fight, and Follow disease for improved patient outcomes [3] - The company has been providing radiopharmaceutical solutions for nearly 70 years and is headquartered in Massachusetts, with additional offices in New Jersey, Canada, Germany, Sweden, and Switzerland [3] Upcoming Event - Brian Markison, the Chief Executive Officer of Lantheus, will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 at 7:00 a.m. ET [1] - A live webcast of the presentation will be accessible through the Investors section of the company's website, with a replay available for at least 30 days post-event [2]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Lantheus Holdings, Inc. for possible violations of federal securities laws and unlawful business practices following disappointing financial results and a significant drop in stock price [1][3]. Financial Performance - On August 6, 2025, Lantheus reported second quarter 2025 results with earnings-per-share (EPS) and revenue figures that missed market expectations [3]. - The company lowered its full year 2025 revenue guidance from $1.550 billion - $1.585 billion to $1.475 billion - $1.51 billion, and adjusted fully diluted EPS guidance from $6.60 - $6.70 per share to $5.50 - $5.70 per share [3]. - Consolidated net revenue for the second quarter was $378 million, a decrease of 4.1%, with sales from the radiopharmaceutical oncology product PYLARIFY contributing $250.6 million, down 8.3% [3]. Stock Market Reaction - Following the announcement of the disappointing results, Lantheus's stock price fell by $20.76 per share, or 28.58%, closing at $51.87 per share on August 6, 2025 [3].